BEIJING (AFP) – A USD60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials said, the first details of a mass rollout for an as-yet unproven vaccine.
Officials in Jiaxing city said on Thursday residents aged between 18 and 59 with “urgent needs” can seek consultations at clinics for a Sinovac Biotech vaccine that authorities have been giving to groups such as medical workers.
The statement from Jiaxing’s centre for disease control and prevention did not specify what constituted “urgent needs”.
Authorities did not say how many people in the city had been given the vaccine, which comes in two doses, administered up to 28 days apart and costing a total of CNY400 (about USD60).
China has already given hundreds of thousands of essential workers at ports, hospitals and other high-risk areas across the country an experimental vaccine, according to officials.
But even as 11 Chinese vaccines have entered clinical trials – with four in advanced Phase Three – none has been approved for mass market distribution.
China is desperate to win the global race for a vaccine against a virus which emerged in the central city of Wuhan, as it seeks to complete its narrative of recovery from the public health and economic calamity.
China approved some candidates for emergency use, with officials saying they have not seen serious adverse reactions.
Beijing also made bold predictions on a broader rollout before year-end as it battles a storm of international criticism over its early handling of the outbreak.
Health officials told a press conference last month the country expects to be able to produce 610 million vaccine doses annually by year-end, stressing it would be affordable.
China signed up to a World Health Organization-led bid to ensure future COVID-19 vaccines are distributed to developing countries, the biggest economy yet to join the attempt to control the pandemic.
Beijing has not given details on how much money it would commit to the deal, which has a fundraising goal of USD2 billion and aims to provide 92 low and middle-income countries with a future vaccine.